AnaBios News

News 2017-09-19T18:14:21+00:00

​​​​AnaBios to attend the 2017 Society of Toxicology Annual Meeting and Exposition in Baltimore, MD, U.S.A.

Upcoming in March, AnaBios will be presenting and exhibiting at the 2017 Society of Toxicology Annual Meeting and Expo, taking place at the Baltimore Convention Center, March 13th – 16th. AnaBios’ exhibit/booth number is #519.  Dr.’s Paul Miller and Najah Abi-Gerges will be in attendance to discuss the latest in research and service offerings. Poster presentations are as follows:

By | February 13th, 2017|

AnaBios invited to speak at prestigious Gordon Research Conference in Ventura, CA

AnaBios invited to speak at prestigious Gordon Research Conference in Ventura, CA, February 6th – 10th, 2017. ​​Dr. Najah Abi-Gerges, Scientific Director for AnaBios, has been accepted to speak at The Gordon Research Conference in February 2017, in Ventura, CA. Dr. Abi-Gerges will speak on " “Proarrhythmia Predictions Using Primary Human Cardiomyocytes."   The Gordon Research Conference, founded in 1941, is a prestigious international scientific conference, dedicated to highlighting [...]

By | February 6th, 2017|

Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform

December 5, 2016: Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today a collaboration to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain. The goal of the collaboration is to accelerate Purdue's Nav1.7 sodium ion channel drug candidates utilizing AnaBios' Phase-X® discovery platform to develop treatments for chronic pain.   Under [...]

By | December 5th, 2016|

Purdue Pharma CEO discusses the alliance with AnaBios at BIO-Europe 2016 in Stockholm, Sweden

April 4 - 6, 2016: Purdue Pharma CEO discusses the alliance with AnaBios at BIO-Europe 2016 in Stockholm, Sweden. Purdue Pharma CEO, Mark Timney, discusses the company's strategy and the alliance with AnaBios, in an interview with Pharma Intelligence's Mike Ward. An excerpt of the interview is available by clicking on the video.   Video: 2016 Purdue CEO discusses the Purdue-AnaBios alliance and plans for growth away from opioid market [...]

By | April 4th, 2016|

AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic

September 28 - October 1, 2015: AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic.   The findings of collaborative work between AnaBios, AbbVie, Novartis and Roche were presented at the 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic. The presentation summarizes the results obtained employing Phase-X® ex-vivo human-based model that uses ventricular trabeculae from donor hearts, combined with sharp-electrode continuous recordings of [...]

By | September 28th, 2015|

Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment

September 22, 2015: Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment Project aims to Advance Nav1.7 Sodium Ion Channel Drug Candidates with Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today the intent to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel compounds for the treatment of chronic pain. The joint research and development effort [...]

By | September 22nd, 2015|